To investigate quantitative characteristics of humoral immunity in patients with hepatitis C, we established an enzyme-linked immunospot (ELISPOT) assay for detection of anti-HCV-secreting B cells. ROC curve analysis demonstrated 100% specificity and 58% to 92% sensitivity for detecting B-cell responses to NS5b, NS3, E2 and core antigens. The median sum of anti-HCV secreting B cells to all HCV antigens tested was significantly higher in 39 patients with chronic hepatitis C (47.3 spot forming cells (SFC) /10 6 PBMC) than in 9 recovered subjects (15. Of these, 48 subjects were selected randomly to assess humoral immune responses at the B-cell level. The "chronic hepatitis C" group included 39 subjects who were positive for anti-HCV antibodies (EIA-2 and RIBA-3) and positive for HCV RNA. The "recovered" group included 9 anti-HCV positive subjects who were HCV RNA-negative by qualitative polymerase chain reaction on at least two consecutive visits. The patients' characteristics are summarized in Table 1 . Eleven volunteer blood donors without a history of HCV infection served as controls. All subjects were negative for hepatitis B surface antigen and antibodies to the human immunodeficiency virus. The study protocols were reviewed and approved by the appropriate institutional review boards, and all subjects gave their written informed consent.
Statistical Analysis
The Mann-Whitney U test or student's t-test was used to analyze continuous variables as appropriate. Spearman's rank order correlations were used to evaluate the frequencies of anti-HCV antibody-secreting B cells to each antigen and to the clinical features. A P value of ≤ 0.05 was considered significant. Although SFC/10 6 PBMCs was expressed in this study, the statistics were significant whether this was used or the raw counts were used. Statistical analyses were performed using SigmaStat (version 2.03, SPSS Inc., Chicago, IL). Receiver-operating characteristic (ROC) curve analysis was performed with the MedCalc 7.0 program (http://www.medcalc.be). The best cutoff values of the ELISPOT assays were chosen automatically by the MedCalc 7.0 program as the spot forming cells with the highest diagnostic accuracy, i.e., the sum of the false-negative and false-positive rates was minimized. The respective overall diagnostic values were expressed using the area under the curve (AUC).
Results

Optimal Cutoff Values for ELISPOT Assay
To determine the optimal cutoff values for the B cell ELISPOT assay in differentiating patients with HCV infection from HCV seronegative blood donors, ROC curve analysis was performed. The ROC curves for the ELISPOT assay detecting anti-HCV IgG specific-B cells were obtained by calculations made using the values obtained from 48 patients with HCV infection and the 11 HCV-negative volunteer blood donors. The selection of the optimal cutoff point value was based on the level at which the accuracy was maximum (see Patients and Methods). The optimal cutoff values, sensitivity, specificity, positive predictive values, negative predictive values, and calculated AUCs to all HCV antigens are listed in Table 2A . In our ELISPOT assay, the values of sensitivity were from 58% to 92%, and the values of specificity were 100%. The results of AUC were constantly high in the ELISPOT assays to all antigens, and the values of AUC were between 0.71 (NS5B antigen) and 0.94 (core and E2 antigens).
After we defined the optimal cutoff value for each antigen, we determined the frequencies of anti-HCV IgG-secreting B cells in 48 patients with HCV infection. The prevalence of anti-HCV IgG-secreting B cells during HCV infection specific for the various antigens were core (92%), E2 (92%), NS3 (77%), and NS5B (58%) ( Table 2A) .
We further assessed the optimal cutoff values for the ELISPOT assay detecting anti-HCV IgM-secreting B cells using ROC curve analysis in 43 patients with HCV infection and in 6 HCV-negative blood donors (Table 2B) . The values of AUC were from 0.73 (NS5B antigen) to 0.94 (core antigen). The prevalence of anti-HCV IgM-secreting B cells was from 54% (NS5B antigen) to 84% (core antigen) (Table 2B ). In this study, the B-cell ELISPOT assay showed high specificity (91% to 100%) and sensitivity (58% to 92%) to all HCV antigens by analysis of the ROC curves and thus achieved high diagnostic accuracy. Although there was a general problem that raw numbers of SFC were low, statistical analysis and prior publications 28, 29 suggest that these small differences are consistent and relevant. Of note, individuals infected with non-genotype1 variants were strongly positive in this assay which utilized only genotype1-derived antigens. This suggests that genotype 1 contains conserved epitopes that will allow the ELISPOT assay to assess humoral immune responses to HCV irrespective of genotype ( Fig. 2) , with the caveat that we did not assess genotypes 4, 5 and 6 that are rare in the US.
Detection and Quantitation of Anti-HCV Antibody-Secreting B Cells
ELISPOT assays have been used as sensitive and specific tools to measure B cell responses in autoimmune diseases 28, 29 and viral infections including cytomegalovirus 15 , rotavirus 16 , measles virus 17 , and hepatitis B virus, 18, 19 as well as to evaluate responses to bacterial 30 and viral vaccines. 18, 19 Other reports demonstrate that ELISPOT is able to detect and numerate antigen-specific memory B cells in PBMCs after in vitro stimulation in both autoimmune diseases and viral infection. 31, 32 Thus, the B-cell ELISPOT assay might be a useful tool to detect anti-HCV-specific memory B cells, and to monitor the efficacy of future HCV vaccines.
Interestingly, this study showed a strong correlation between the numbers of anti-HCV IgG-secreting B cells to the core and E2 antigens and the values of serum transaminases. The clinical significance of these observations is unknown, but raises the possibility that antibody can contribute to liver cell injury. In addition, Ni et al. 33 recently
reported that 10 of 36 hepatitis C patient samples showed increased B cell frequencies that correlated with the degree of hepatic fibrosis. There are insufficient histologic data in our study to assess whether the numbers of anti-HCV antibody-secreting B cells correlate with the degree of fibrosis as well as biochemical evidence of inflammation.
The median numbers of the sum of anti-HCV IgG-secreting B cells to nonstructural antigens were significantly higher in patients with chronic hepatitis C than in the recovered patients. Similarly, an HCV-specific B cell response was more frequently detected in patients with chronic hepatitis C than in recovered subjects (92% vs. 56%, P=0.017) and was directed against a broader range of HCV antigens, particularly to NS3. In contrast, CD4 T-cell responses to NS3 epitopes are greatest in patients who recover from HCV infection. 34, 35 We have also developed and evaluated the ELISPOT assay for detecting anti-HCV IgM-secreting B cells. It has been reported that IgM anti-HCV in serum might be predictive of viral clearance in acute hepatitis C or response to interferon therapy. [36] [37] [38] [39] [40] However, these results have been controversial and other studies have shown a significant correlation between IgM anti-HCV levels in serum and the recurrence of hepatitis C post-liver transplantation. 41, 42 In this study, we found that Overall, this study, as do studies of HCV-specific neutralizing antibodies, 26, 27 suggest that the humoral arm of the HCV immune response is not a critical element of spontaneous viral clearance. However, because of the difficulty in obtaining serial acute-phase PBMC collections from recovering subjects, our study does not exclude a role for antibody mediated viral clearance early in HCV infection. Sequential acute phase ELISPOT IgM testing of PBMC is planned in forthcoming chimpanzee infectivity studies.
Nonetheless, studies of neutralizing and anti-envelope antibodies 26, 27 , that measured serial acute phase serum samples from recovering subjects, did not show that such antibodies correlated with viral clearance. Rather, it appears in those studies and the current study that antibodies to HCV increase in strength and broadness of reactivity during the course of chronic infection, presumably because of persistent antigenic stimulation. This is in contrast to cell-mediated immunity that is markedly diminished in chronically infected as compared to recovered subjects. This dichotomy between the humoral and cellular immune response to HCV is intriguing and suggests T-cell tolerance in the absence of B-cell tolerance.
It is interesting to speculate on the role that antibody might play in HCV infection.
First, it seems reasonable that such antibodies complexed to virus would reduce the level of free virus and diminish transmission to others. This reduction in free virus in addition to lowered viral load might explain the relative rarity of sexual and perinatal transmission during chronic HCV infection. More intriguing is whether such antibodies establish the set point for viral load during chronic infection. It is known that viral loads are highest early in HCV infection prior to the appearance of antibody 43 and that chronically infected patients establish a lower and relatively constant level of viremia. 44 It appears that production and elimination of virus achieve a steady state. This steady state is probably multifactorial in origin, but antibody may play a key role. When patients in a steady state are immunosuppressed at the time of transplantation 45 or when coinfected with human immunodeficiency virus 46 , the viral load increases, supporting an immunologic role for viral containment even in the absence of clearance. A deleterious function of anti-HCV is that it serves to drive quasispecies evolution making it increasingly hard for the immune system to achieve viral clearance. Farci et al. have
shown in both humans and chimpanzees 47 , that the appearance of antibody coincides with increasing viral diversity and complexity and predicts progression to chronic infection. Cutoff values were determined by making ROC curves and are expressed as spot forming cells/10 6 PBMCs. Cutoff values were determined by making ROC curves and are expressed as spot forming cells/10 6 PBMCs.
NOTE: All the AUC were significantly higher than a 0.500 nonpredictive value (P<0.001 for all comparisons).
Abbreviations: AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value.
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